Rainer Blair, Danaher CEO (Photo by Lintao Zhang/Getty Images)
October 25, 2023 07:20 AM EDT
China
Outsourcing
Pharma

Dana­her’s third-quar­ter rev­enue from biotech ser­vices down 19% amid slow­down in Chi­na, US

Ayisha Sharma

News Reporter

An an­tic­i­pat­ed re­duc­tion in biotech sales con­tributed to Dana­her’s third-quar­ter per­for­mance drop­ping rel­a­tive to last year, the com­pa­ny re­vealed Tues­day. This is in the midst …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times